Mestry Snehal Nitin, Dhodi Jayesh Bachu, Kumbhar Sangita Balbhim, Juvekar Archana Ramesh
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai 400019, India.
J Tradit Complement Med. 2016 Jul 13;7(3):273-280. doi: 10.1016/j.jtcme.2016.06.008. eCollection 2017 Jul.
With an objective to develop Complementary and Alternative Medicine for the treatment of diabetic nephropathy, the present study investigated the protective effects of methanolic extract of leaves (MPGL) in streptozotocin-induced diabetic nephropathy. Diabetic nephropathy has become a leading cause of end stage renal failure worldwide. , due to its anti-diabetic, anti-inflammatory and antioxidant activities may retard the progression of diabetic nephropathy. In this study, diabetes was induced by a single injection of streptozotocin (STZ, 45 mg/kg, i.p.) in rats. STZ-diabetic rats were treated with oral doses of MPGL (100, 200 and 400 mg/kg) for 8 weeks. At the end of the experimental period, body and kidney weight and blood glucose levels were determined. Serum and urine parameters were investigated. Antioxidant enzymes and lipid peroxide levels were determined in the kidney along with histopathological examination of the same. MPGL significantly increased body weight, lowered blood glucose levels and ameliorated kidney hypertrophy index in the STZ-diabetic rats. The extract also decreased the levels of creatinine, blood urea nitrogen, total cholesterol, triglycerides, advanced glycation end products and albumin in serum and urine, respectively. MPGL significantly increased the antioxidant parameters in the kidney. Histological evaluation revealed that MPGL treated STZ-diabetic rats demonstrated reduced vacuolar degeneration of tubules; periodic acid Schiff base (PAS) positivity staining intensity in glomeruli and basement membrane thickening. Present findings provide experimental evidence that MPGL has potential antioxidant, antihyperglycemic and anti-glycation activities which might be helpful in slowing the progression of diabetic nephropathy.
为了开发用于治疗糖尿病肾病的补充和替代医学,本研究调查了叶甲醇提取物(MPGL)对链脲佐菌素诱导的糖尿病肾病的保护作用。糖尿病肾病已成为全球终末期肾衰竭的主要原因。由于其抗糖尿病、抗炎和抗氧化活性,可能会延缓糖尿病肾病的进展。在本研究中,通过单次腹腔注射链脲佐菌素(STZ,45mg/kg)诱导大鼠患糖尿病。给STZ诱导的糖尿病大鼠口服MPGL(100、200和400mg/kg),持续8周。在实验期结束时,测定体重、肾脏重量和血糖水平。研究血清和尿液参数。测定肾脏中的抗氧化酶和脂质过氧化物水平,并对肾脏进行组织病理学检查。MPGL显著增加了STZ诱导的糖尿病大鼠的体重,降低了血糖水平,并改善了肾脏肥大指数。该提取物还分别降低了血清和尿液中肌酐、血尿素氮、总胆固醇、甘油三酯、晚期糖基化终产物和白蛋白的水平。MPGL显著增加了肾脏中的抗氧化参数。组织学评估显示,MPGL治疗的STZ诱导的糖尿病大鼠肾小管空泡变性减少;肾小球中高碘酸席夫碱(PAS)阳性染色强度和基底膜增厚减轻。目前的研究结果提供了实验证据,表明MPGL具有潜在的抗氧化、降血糖和抗糖基化活性,这可能有助于减缓糖尿病肾病的进展。